Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bovax 9-valent HPV Vaccine Immunobridging Study
NCT04895020Phase 3Recruiting
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- May 2021
- Primary completion
- Jan 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoint: Primary immunogenicity objective (Seroconversion rate/GMT). Started May 2021; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04895020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895020.